China’s pharmaceutical market is constantly growing and is the second-largest pharmaceutical industry in the world, after the United States. It is estimated to reach $161.8 billion by 2023, with an average growth rate of 5% in the coming years, taking a 30% share of the global market. The acceleration of new drug access, changing regulatory […]

Read More →

Sourcing or importing the IMPs and their supportive products is a challenging process for many researchers and this is more prominent with the countries like Japan and China where understanding the regulatory is difficult due to the language barriers and rapid changing norms for making imports.  Many key players in logistics are unclear about the […]

Read More →

In recent years there is a huge leap in the pharma industry towards rare diseases and orphan drug developments due to the great support from regulatory authorities such as faster approval timelines, supportive regulatory frameworks, financial incentives, and many more. Currently, large pharmaceutical companies are extremely active in the orphan drugs market. Novartis, GSK, Roche, […]

Read More →

Revised Chinese regulations that brought a lot of changes in clinical trials and product registrations were received with lots of questions. If you have got questions that are yet unanswered, you are not alone. Many researchers, developers, and managers are not sure about one aspect or another on how to comprehend, act, or change their […]

Read More →

Do you know any product segment, where one does not get to encounter Chinese products? Well, hardly any. It has been the focus of the Chinese government for the past several decades to dominate various industrial sectors, including pharmaceuticals. While China has been the big production factory for generic drugs and API ingredients for many […]

Read More →